Last reviewed · How we verify
NCT05767242
Early Neurophysiological Markers of Language Impairments
trial testing Electrophysiological recording in Development, Infant in 100 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | IRCCS Eugenio Medea |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 21 February 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Electrophysiological recording
- Behavioral assessment
Conditions studied
- Development, Infant — all drugs for Development, Infant →
- Development, Language — all drugs for Development, Language →
- Developmental Language Disorder — all drugs for Developmental Language Disorder →
- Learning Disabilities — all drugs for Learning Disabilities →
Sponsor
IRCCS Eugenio Medea — full company profile →
Who can join
Adults 6 Months to 8, any sex, with Development, Infant or Development, Language. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present project aims at identifying very early electrophysiological risk markers for language impairments. The long-term goals of the study include the characterization of learning developmental trajectories in children at high risk for language impairments. In this project, all the infants of the Medea BabyLab cohort are followed-up until school age. Since these infants have complete information on early electrophysiological markers, the final goal of the project is the characterization of their learning developmental trajectories and the construction of a multi-factor prognostic model that includes the neurophysiological processes underlying basic-level skills as potential biomarkers for predicting later reading and spelling skills.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Baseline EEG in the first year of life: Preliminary insights into the development of autism spectrum disorder and language impairments.
Piazza C, Dondena C, Riboldi EM, Riva V, et al · · 2023 · cited 9× · PMID 37534149 · DOI 10.1016/j.isci.2023.106987
Verify or expand the search:
- PubMed search for NCT05767242
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Development, Infant
Currently open trials in the same condition.
- NCT06396520 — Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy · recruiting
- NCT05230199 — Sensory Optimization of the Hospital Environment · NA · recruiting
- NCT05834907 — Hands and Hearts Together · NA · recruiting
- NCT05665049 — Social Transfers for Exclusive Breastfeeding · NA · active not recruiting
- NCT05527080 — Development of Motility and Cognition in Infants · recruiting
Other IRCCS Eugenio Medea trials
Trials by the same sponsor.
- NCT07095062 — Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome. · NA · recruiting
- NCT06993389 — AI-based Model for Rehabilitation Engagement and Motor Performance Evaluation in Pediatric Patients · recruiting
- NCT06999850 — Implementation and Validation of Instrumented Stair Climb Test · NA · recruiting
- NCT06666777 — Speech Therapy and Parenting for Early Socio-communicAtive sKills · NA · recruiting
- NCT07470138 — Sleep Disturbance in Subjects With Autism Spectrum Disorders (ASD) in Preschool Age (18-60 Months) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05767242 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS Eugenio Medea
- Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05767242.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing